Navigation Links
iPierian Closes $22 Million Series B Financing Led By Google Ventures
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing.  The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures.  All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.  The Series B financing brings the total amount of equity capital raised by iPierian to $54 million since its inception in 2007.

Krishna Yeshwant, M.D., a partner at Google Ventures, will join the iPierian Board of Directors.  "iPierian's work with iPSCs is incredibly exciting.  The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases," said Dr. Yeshwant.  "The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will dramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission."

Corey Goodman, Ph.D., chairman of the iPierian Board, commented, "We are pleased to welcome our new investors.  Our rapid scientific progress is allowing us to harness iPS technology as a research platform to identify novel therapeutics for patients with major unmet medical needs."

In conjunction with the closing of the Series B financing, Michael C. Venuti, Ph.D., president and chief scientific officer since February 2010, will assume the role of chief executive officer, and will join the Board of Directors. John P. Walker, who has been the CEO of iPierian since February 2009, is stepping down for personal reasons from his position as CEO and member of the Board of Directors and will remain employed by the company as a senior advisor.

"We thank John for his inspired leadership, and I personally value John's continued input as a senior advisor," said Dr. Venuti.  "Under his leadership, the company has emerged as the leader in utilizing the iPSC platform for drug discovery, as evidenced by industrializing the technology, the significant progress with three proprietary programs, and recently being awarded research grants from the California Institute for Regenerative Medicine (CIRM) and the National Institutes of Health (NIH)."

Mr. Walker added, "I am confident in handing over the day-to-day responsibilities of the company to Mike.  He has demonstrated an enviable track record in drug discovery, management and business development, all of which will be important in building on the excitement of this paradigm shift in drug discovery."

For additional information about Dr. Krishna Yeshwant and Google Ventures, please visit www.google.com/ventures.  

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.  

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF. 

iPierian is located in South San Francisco, California.  For more information, please visit www.ipierian.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
4. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
5. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
6. Curemark Closes Series A Financing
7. Blue Belt Technologies, Inc. Closes Series A Financing
8. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
9. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
10. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
11. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical ... high performance apparel for healthcare and other demanding applications, ... Chief Executive Officer. He replaces Dale Pfost , ... Chairman. Mr. Bold is also joining Vestagen,s Board of ... new class of active barrier technologies that combines fluid ...
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... -- Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko ... as president, Americas Operations, for Astellas US LLC, with ... South America , effective April 1, 2016.  Robinson previously ... in the United States -- a ... , who is retiring in June 2016.  --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
Breaking Medicine News(10 mins):